SEC Form 4 · accession 0001209191-18-033657
TRANSENTERIX INC. · TRXC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul A Laviolette
Director
Period of report
May 24, 2018
Accepted (ET)
May 29, 2018 · 7:01 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000876378
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | May 24, 2018 | A | 40,950 | — | A | 40,950 | D | |
| Common StockF4 | holding | — | — | — | 7,338,352 | I | By LP | |
| Common StockF5 | holding | — | — | — | 208,340 | I | By LP |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option AwardF2,F6 | $3.17 | May 24, 2018 | A | 71,580 | A | — | May 24, 2028 | Common Stock | 71,580 | 71,580 | D |
Explanation of responses
- F1Represents restricted stock units. Each restricted stock unit represents the right to receive one share of the Registrant's common stock.
- F2The Reporting Person elected to receive his annual board of directors' compensation in equity.
- F3The restricted stock units remain subject to forfeiture until the first anniversary of the date of grant or, if earlier, the date of the next annual meeting of stockholders, as long as the reporting person remains in continuous service during the vesting period.
- F4Shares held by SV Life Sciences Fund IV, L.P. Paul LaViolette is a partner of SVLSF IV, LLC and a control person of SV Life Sciences Fund IV, L.P.
- F5Shares held by by SV Life Sciences Fund IV Strategic Partners, L.P. Paul LaViolette is a control person of SV Life Sciences Fund IV Strategic Partners, L.P.
- F6The vesting schedule is 25% of the stock option award on each of July 1, 2018, October 1, 2018, January 1, 2019 and April 1, 2019.